A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35286211.
- Also identified by DOI 10.1073/pnas.2200065119 and PMC identifier 8944267.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
SignificanceConcern has increased about the pandemic potential of Nipah virus (NiV). Similar to SARS-CoV-2, NiV is an RNA virus that is transmitted by respiratory droplets. There are currently no NiV vaccines licensed for human use. While several preventive vaccines have shown promise in protecting animals against lethal NiV disease, most studies have assessed protection 1 mo after vaccination. However, in order to contain and control outbreaks, vaccines that can rapidly confer protection in days rather than months are needed. Here, we show that a recombinant vesicular stomatitis virus vector expressing the NiV glycoprotein can completely protect monkeys vaccinated 7 d prior to NiV exposure and 67% of animals vaccinated 3 d before NiV challenge.
Medical subject headings
- Henipavirus Infections
- Nipah Virus
- Primate Diseases
- Vaccines, Synthetic
- Viral Vaccines